India, Aug. 7 -- SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, Thursday announced that the Independent Data Monitoring Committee (IDMC) has completed a pre-specified analysis of the Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML), and has issued a positive recommendation to continue the trial without modification.
The IDMC concluded that the risk-benefit profile of GPS supports continued evaluation under the current study protocol. No safety concerns were identified, and available efficacy data were consistent with expectations for continued trial conduct.
The study completed enrollme...